Short- and long-term opioid use in survivors of subarachnoid hemorrhage

Mahta, Ali; Anderson, Matthew N.; Azher, Aidan I; Mahmoud, Leana; Dakay, Katarina; Abdulrazeq, Hael; Abud, Alexander; Moody, Scott; Reznik, Michael; Yaghi, Shadi; Thompson, Bradford B.; Wendell, Linda C.; Rao, Singiresu S.; Potter, N. Stevenson; Cutting, Shawna; Grory, Brian Mac; Stretz, Christoph; Doberstein, Curtis E.; Furie, Karen L.

doi:10.1016/j.clineuro.2021.106770

Cited by 5 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opioids are generally used in the acute setting following a SAH although alternative treatment must be explored due to the potential of opioid dependence [ 42 , 43 ]. More than one-third of patients with SAH have persistent headaches, hence the need to explore long-term analgesic options [ 44 ].…”

Section: Non-traumatic Ichmentioning

confidence: 99%

Secondary headaches - red and green flags and their significance for diagnostics

Wijeratne

Korajkic

et al. 2023

eNeurologicalSci

View full text Add to dashboard Cite

Section: Non-traumatic Ichmentioning

confidence: 99%

Secondary headaches - red and green flags and their significance for diagnostics

Wijeratne

Korajkic

et al. 2023

eNeurologicalSci

View full text Add to dashboard Cite

“…108,109 Use of PAT for neurosurgical patients with SUD should also be considered. 46,79,110,111 For example, in spine surgery candidates, given that smoking is associated with lower fusion rates, and psilocybin-assisted therapy has shown promise in early trials for nicotine and opioid addiction, PAT could be considered preoperatively to improve fusion rates and to reduce opioid dependence postsurgery which may occur in up to 1/3 of such patients. 6,45,100,112,113 RUMINATIVE DISORDERS, SUD, AND PTSD BEING TARGETED WITH NEUROMODULATION DBS and TMS have both shown variable efficacy or been considered for treating OCD, anorexia, SUD, depression, and PTSD.…”

Section: Mood Disorders and Addictionmentioning

confidence: 99%

“…NA, not available; SUD, substance use disorders.aSUD includes for alcohol, opioids, and/or nicotine.Refer to references: 76-104 .…”

Section: Mood Disorders and Addictionmentioning

confidence: 99%

“…As shown in Table 2, potential targets for PAT are the depression, anxiety, and SUD that are common, under-reported, and often undertreated in patients with brain tumors, stroke, SAH, TBI, spinal cord injury, chronic spinal disability, other pain syndromes, and Parkinson disease. 3,4,76-104 For example, psilocybin-assisted therapy may help some of these patients gain greater acceptance of their disability, reduce apathy, and promote living more fully. 82,83…”

Section: Mood Disorders and Addictionmentioning

confidence: 99%

See 1 more Smart Citation

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

et al. 2022

View full text Add to dashboard Cite

After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and ketamine are increasingly appreciated as neuroplastogens given their potential to fundamentally alter mood and behavior well beyond the time window of measurable exposure. Imaging studies with psychedelics are also helping advance our understanding of neural networks and connectomics. This resurgence in psychedelic science and psychedelic-assisted therapy has potential significance for the fields of neurosurgery and neuro-oncology and their diverse and challenging patients, many of whom continue to have mental health issues and poor quality of life despite receiving state-of-the-art care. In this study, we review recent and ongoing clinical trials, the set and setting model of psychedelic-assisted therapy, potential risks and adverse events, proposed mechanisms of action, and provide a perspective on how the safe and evidence-based use of psychedelics could potentially benefit many patients, including those with brain tumors, pain syndromes, ruminative disorders, stroke, SAH, TBI, and movement disorders. By leveraging psychedelics' neuroplastic potential to rehabilitate the mind and brain, novel treatments may be possible for many of these patient populations, in some instances working synergistically with current treatments and in some using subpsychedelic doses that do not require mind-altering effects for efficacy. This review aims to encourage broader multidisciplinary collaboration across the neurosciences to explore and help realize the transdiagnostic healing potential of psychedelics.

show abstract